
Opinion|Videos|February 3, 2025
Enhancing Multidisciplinary Coordination and Treatment Planning Through In-House Testing
Author(s)Vivek Subbiah, MD, Lucio N. Gordan, MD
Panelists discuss how in-house testing facilities significantly enhance multidisciplinary coordination by enabling rapid result turnaround and real-time treatment adjustments. This streamlined process facilitates immediate care planning among specialists, leading to faster clinical decisions and reduced wait times. Studies demonstrate that on-site testing correlates with improved patient outcomes through earlier interventions, decreased length of stay, and enhanced treatment monitoring, ultimately supporting more efficient and responsive patient care delivery.
Advertisement
Episodes in this series

Video series above is prompted by the following:
- How has in-house testing impacted multidisciplinary coordination and treatment planning at your institution?
- Discuss the impact of in-house testing on patient outcomes and overall quality of care.
Advertisement
Related to this article

Sara Nunnery, MD, MSCI, and Irene M. Kang, MD, discuss toxicity and monitoring considerations for the use of ADCs in metastatic TNBC.

ASCO’s ctDNA guidelines support testing for genetic alterations in select scenarios but do not endorse it for residual disease or recurrence monitoring.

Komal Jhaveri, MD, FACP, discusses the design of the SERENA-6 trial and larger questions for the breast cancer field that remain after seeing its results.

The oral PARG inhibitor ETX-19477 earned fast track status for BRCA-mutated, HR-positive, HER2-negative unresectable or metastatic breast cancer.

T-DXd plus pertuzumab was approved in China as first-line treatment for unresectable or metastatic HER2-positive breast cancer.

Komal Jhaveri, MD, FACP, discusses the role of CDK4/6 inhibitors for patients with hormone receptor–positive disease and how oral SERD use is changing.

A surgical team from Huntsman Cancer Institute at the University of Utah has performed the first robotic mastectomy in the Mountain West.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
Dr Wainberg on INCB161734 Activity in Refractory Pancreatic Cancer
3
European Commission Approves Teclistamab Plus Daratumumab for R/R Myeloma
4
China’s NMPA Accepts NDA for Opamtistomig in Pretreated Advanced Extrapulmonary NEC
5

